The global uterine fibroid embolization device market size was USD 5,231.30 Mn in 2022 and is likely to reach USD 7,679.10 Mn by 2031, expanding at a CAGR of 4.35% during 2023–2031. Increasing awareness regarding various techniques among people is likely to fuel the market.
Uterine fibroid embolization (UFE) is a minimally invasive procedure used to treat uterine fibroids. During UFE, a small catheter is inserted into the femoral artery in the groin and guided to the uterine arteries that supply blood to the fibroids. Small particles of gelatin, sand, or plastic are injected through a catheter and into the uterine arteries, blocking the blood flow to the fibroids, causing them to shrink.
A small catheter is typically used a device employed in UFE, which is inserted through a small incision in the skin. This catheter has a tiny camera on one end, allowing the healthcare professionals to see inside the body and guide it to the uterine arteries. The particles used in UFE are usually made of a material that is biocompatible and safe for the body.
UFE is a safe and effective treatment option for women with uterine fibroids who experience symptoms such as heavy menstrual bleeding, pelvic pain, or pressure. It is less invasive than traditional surgery and has a shorter recovery time. Most women return to normal activities within a week after the procedure.
As with any medical procedure, certain risks are associated with UFE, including infection bleeding, and damage to surrounding tissues. Women considering UFE should speak with their doctor to determine if it is the right treatment option for their situation.
The market report finds that the COVID-19 pandemic restrained the market, due to the continuous decline in elective surgeries. During the pandemic, hospital access was restricted to non-essential care and O&P clinics are temporarily closed.
Uterine Fibroid Embolization Device Market Dynamics
Major Drivers
Increasing prevalence of uterine fibroids is expected to drive the market. Fibroid is common at the age of 30 and 40 and growing number of women around the globe is likely to fule the market.
Rising preference for minimally invasive surgeries is expected to boost the market. Fibroids put pressure on the bladder or the rectum and cause frequent urination.. Thus, women prefer minimally invasive surgery reduces blood loss, decreased postoperative pain, and fast recovery.
The Food & Drug Administration has approved the first medical option an oral medication with the brand name Oriahnn. It is specifically for reducing heavy menstrual bleeding caused by uterine fibroids.
Restraints
The high cost of medical devices implemented by the government is a major factor restraining the uterine fibroid embolization devices market. Moreover, strict regulations imposed on the treatments are expected to create challenges in the market.
Opportunities
Developments in treatment procedures are expected to create lucrative opportunities for the market players. Increasing research & development (R&D) is expected to offer lucrative opportunities in the market.
Scope of Uterine Fibroid Embolization Device Report
The global market report includes research report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Uterine Fibroid Embolization Device Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Technology (Laparoscopic, Embolization, Surgical, and Ablation), and Mode of Treatment (Minimally Invasive Treatment, Invasive Treatment, and Non-Invasive Treatment)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Gynesonics; Boston Scientific Corporation; Merit Medical Systems; KARL STORZ Endoscopy-America, Inc.; BioSpace.com; Hologic, Inc.; Cook; Ferring B.V.; Smith+Nephew; Stryker; COOPERSURGICAL, INC.; Olympus America; Aetna Better Health of Pennsylvania; and Medical Device Business Services, Inc.
|
Uterine Fibroid Embolization Device Market Segment Insights
Technology Segment Analysis
Based on technology, the uterine fibroid embolization device market is divided into laparoscopic, embolization, surgical, and ablation. The laparoscopic segment is expected to expand at a significant pace during the projection period. Laparoscopic surgery is done through small incisions by using small tubes and tiny cameras. The benefits of this technique include fast recovery time, less pain, and reduced scarring.
The surgical segment is estimated to expand at a robust pace during the forecast period, due to the increasing number of hysterectomy and myomectomy surgical procedures. During UFE, a catheter is inserted within a blood vessel in the leg or wrist and shown by X-ray images.
Mode of Treatment Segment Analysis
On the basis of the mode of treatment, the global market is segregated into minimally invasive treatment, invasive treatment, and non-invasive treatment. The minimally invasive treatment segment is projected to expand at a considerable CAGR during the forecast period. This procedure temporarily stops the blood flow to certain organs. It is often used to treat women with uterine fibroids.
Regional Analysis
In terms of region, the global uterine fibroid embolization device market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, due to the presence of well-established healthcare facilities. Increasing number of uterine fibroids patients and growing healthcare awareness among the population boost the market in the region.
The market in Asia Pacific is anticipated to expand at a rapid pace in the coming years, due to the increasing awareness among patients. Emerging countries such as India and China are increasing the medical tourism sector, which is expected to drive the market.
Segments
The global uterine fibroid embolization device market has been segmented on the basis of
Technology
- Laparoscopic
- Embolization
- Surgical
- Ablation
Mode of Treatment
- Minimally Invasive Treatment
- Invasive Treatment
- Non-Invasive Treatment
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Gynesonics
- Boston Scientific Corporation
- Merit Medical Systems
- KARL STORZ Endoscopy-America, Inc.
- BioSpace.com
- Hologic, Inc.
- Cook
- Ferring B.V.
- Smith+Nephew
- Stryker
- COOPERSURGICAL, INC.
- Olympus America
- Aetna Better Health of Pennsylvania
- Medical Device Business Services, Inc.
Competitive Landscape
Key players in the global uterine fibroid embolization device market are Gynesonics; Boston Scientific Corporation; Merit Medical Systems; KARL STORZ Endoscopy-America, Inc.; BioSpace.com; Hologic, Inc.; Cook; Ferring B.V.; Smith+Nephew; Stryker; COOPERSURGICAL, INC.; Olympus America; Aetna Better Health of Pennsylvania; and Medical Device Business Services, Inc.,These companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide.
- In March 2020, KARL STORZ launched the TELE PACK + compact endoscopy system. It is a portable video system that combines all of the crucial components such as a light source, camera unit, and display needed to allow endoscopic diagnosis and treatment.
- In October 2020, Gynesonics announced to continue to expand Sonata in New York. Sonata is a new innovative incision-free procedure to treat symptomatic uterine fibroids.
Request For Customization
Enquiry Before Buying
Speak With Analyst
